Codagenix Inc., a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, today announced the expansion of its senior management team with three new appointments. Lisa Runco, Ph.D., has been named Director of Operations. Additionally, Sally Yang, M.S., R.A.C. has been appointed Associate Director of Regulatory Affairs, and Lasmy Tea, M.S., M.P.H., has been named Associate Director of Clinical Project Management.
“We are proud to announce the appointment of these three vastly experienced individuals to the growing management team at Codagenix and look forward to benefitting from their expertise as Codagenix anticipates multiple, significant growth opportunities throughout the year,” said J. Robert Coleman, Ph.D., CEO of Codagenix. “The ongoing development of COVI-VAC, our single-dose, live attenuated COVID-19 vaccine, has brought considerable attention to Codagenix’s diverse portfolio of vaccines and our Synthetic Attenuated Virus Engineering (SAVE) platform. Sally, Lasmy and Lisa will be instrumental to maximizing this potential by advancing key operational, regulatory and clinical initiatives.”
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).
